Prognostic significance of Ki-67 in chemotherapy-naive breast cancer patients with 10-year follow-up.

BACKGROUND/AIM In order to define accurate survival outcome in breast cancer, 10-year follow-up is required and such long-term survival information are few and difficult to gather. PATIENTS AND METHODS We recruited 253 breast cancer patients who undertook operation with no prior chemotherapy. Ten-year survival outcomes were evaluated by clinicopathological factors. RESULTS Significant univariate prognostic factors were: T factor, N factor, preoperative values of tumor markers, and biological factors. T-factor, CEA, hormone receptor, and Ki-67 were the final independent prognostic factors of recurrence-free survival through multivariate analysis. The Luminal A group except for the Ki-67-positive cases showed the best survival outcomes, while the HER2-positive or triple-negative (TN) groups showed worse prognosis than the Luminal A group, and Ki-67 was shown to be an excellent prognostic factor in each stage (p<0.01). CONCLUSION Ki-67 has a great potential as a prognostic biomarker while prognostic information of this sort could be beneficial for development of novel therapeutic strategies.

[1]  F. Lacombe,et al.  Modalities of synthesis of Ki67 antigen during the stimulation of lymphocytes. , 1991, Cytometry.

[2]  R. Gelber,et al.  Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  C. Burns,et al.  An audit of local government planning tools for their potential use in addressing community food and nutrition issues. , 2010, Health promotion journal of Australia : official journal of Australian Association of Health Promotion Professionals.

[4]  Mitch Dowsett,et al.  Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. , 2007, Journal of the National Cancer Institute.

[5]  A. Giobbie-Hurder,et al.  Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  C. Perou,et al.  The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes , 2007, Clinical Cancer Research.

[7]  Mitch Dowsett,et al.  Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  F. Penault-Llorca,et al.  Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Pierre-Marie Martin,et al.  Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review , 2011, Breast Cancer Research and Treatment.

[10]  H. Muss,et al.  Recent Advances: Adjuvant Therapy for Older Women With Breast Cancer , 2010, Cancer journal.

[11]  Y. Collan,et al.  Prognostic Value of Proliferation Markers: Immunohistochemical Ki-67 Expression and Cytometric S-Phase Fraction of Women with Breast Cancer in Libya , 2012, Journal of Cancer.

[12]  W. Han,et al.  The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer , 2008, BMC Cancer.

[13]  N. Harbeck,et al.  Personalized treatment of early-stage breast cancer: present concepts and future directions. , 2010, Cancer treatment reviews.

[14]  R. Gelber,et al.  Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  Norman Wolmark,et al.  Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[17]  Y. Niu,et al.  A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments , 2011, Breast Cancer Research and Treatment.

[18]  I. Ellis,et al.  Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. , 1995, British Journal of Cancer.

[19]  R. Gelber,et al.  Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[21]  C. Cornelisse,et al.  Nuclear distribution of the Ki-67 antigen during the cell cycle: comparison with growth fraction in human breast cancer cells. , 1989, Cancer research.

[22]  S. Loi.  Molecular analysis of hormone receptor positive (luminal) breast cancers: what have we learnt? , 2008, European journal of cancer.

[23]  P. Neven,et al.  Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  H. Budka,et al.  Immunohistochemical detection of cell growth fraction in formalin-fixed and paraffin-embedded murine tissue. , 2001, The American journal of pathology.

[25]  F. Révillion,et al.  Intracellular calcium and breast-cancer cell-growth and differentiation. , 1993, International journal of oncology.

[26]  Jane M. Young,et al.  A pilot study to evaluate the impact of involving breast cancer patients in the multidisciplinary discussion of their disease and treatment plan. , 2007, Breast.

[27]  M. Raica,et al.  From conventional pathologic diagnosis to the molecular classification of breast carcinoma: are we ready for the change? , 2009, Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie.

[28]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[29]  A. Luini,et al.  Prognostic value of Ki-67 labeling index in patients with node-negative, triple-negative breast cancer , 2012, Breast Cancer Research and Treatment.

[30]  S. O'toole,et al.  Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53 , 2011, British Journal of Cancer.

[31]  W. Han,et al.  Ki-67 Expression Gives Additional Prognostic Information on St. Gallen 2007 and Adjuvant! Online Risk Categories in Early Breast Cancer , 2009, Annals of Surgical Oncology.

[32]  Mitsuhiro Hayashi,et al.  Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer. , 2010, Experimental and therapeutic medicine.